...completed Warner Chilcott plc (NASDAQ:WCRX)/TaiGen Biotechnology Co. Ltd. Nemonoxacin Topoisomerase IV inhibitor Ph II completed Dong Wha Pharmaceutical Industrial Co. Ltd....

...are expected mid-2012. Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....
...trial. But Iaso will require additional funds beyond an IPO to conduct Phase III testing. Dong Wha...

...community-acquired pneumonia (CAP). Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....

...community-acquired pneumonia (CAP). Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....

...community-acquired pneumonia (CAP). IASO has exclusive rights to zabofloxacin to treat bacterial respiratory infections from Dong Wha Pharmaceutical Industrial Co. Ltd....

...community-acquired pneumonia (CAP). Iaso (formerly Pacific Beach BioSciences Inc.) has exclusive rights to zabofloxacin from Dong Wha Pharmaceutical Industrial Co. Ltd....

...Pacific Beach received exclusive rights to develop and commercialize Dong Wha's zabofloxacin ( PB-101 ) outside of...
...outside of Australia, New Zealand and certain Asian territories to treat bacterial respiratory infections. Dong Wha...
...fluoroquinolone antibiotic has completed Phase I testing. Pacific Beach BioSciences Inc ., San Diego, Calif. Dong Wha Pharmaceutical Industrial Co. Ltd....

...Procter & Gamble Pharmaceuticals Inc.'s deal with Dong Wha Pharmaceutical Industrial Co. exemplifies how the consumer product...
...and their doctors about the product when it reached market. Under this month's deal with Dong Wha...
...PG received exclusive, worldwide rights outside certain Asian countries including Japan, Korea and China, to Dong Wha's...

...All outsourced Year Partner Deal Current status [status at time of deal] 2007 Dong Wha Develop and...

...The deal includes Dong Wha's lead osteoporosis compound, DW1350 , which is in Phase I testing. Dong Wha...
...total of $511 in an undisclosed upfront payment and milestones and is eligible for royalties. Dong Wha Pharmaceutical Industrial Co. Ltd....